Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sernova Corp. (TSX:SVA; OTCQB:SEOVF) announced promising preclinical results for its partnership with Evotec SE, focusing on iPSC-derived islet-like clusters (ILCs) for treating Type 1 Diabetes (T1D). Key findings showcased that Evotec's scalable GMP manufacturing process yields ILCs with high insulin-producing beta cell content and successful glycemic control in diabetic mouse models. Results indicated that ILCs implanted in Sernova's Cell Pouch demonstrated blood sugar normalization akin to human islets over a 320-day study. The companies are on track for an IND filing and Phase 1/2 clinical trial in 2024, aiming to offer a commercially viable off-the-shelf treatment for diabetes. The preclinical data was presented at the IPITA/HSCI/JDRF Summit in April 2023, underscoring the significant potential for a 'functional cure' for T1D.